TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

por Freedman, Rachel A., Gelman, Rebecca S., Anders, Carey K., Melisko, Michelle E., Parsons, Heather A., Cropp, Anne M., Silvestri, Kelly, Cotter, Christine M., Componeschi, Kathryn P., Marte, Juan M., Connolly, Roisin M., Moy, Beverly, Van Poznak, Catherine H., Blackwell, Kimberly L., Puhalla, Shannon L., Jankowitz, Rachel C., Smith, Karen L., Ibrahim, Nuhad, Moynihan, Timothy J., O’Sullivan, Ciara C., Nangia, Julie, Niravath, Polly, Tung, Nadine, Pohlmann, Paula R., Burns, Robyn, Rimawi, Mothaffar F., Krop, Ian E., Wolff, Antonio C., Winer, Eric P., Lin, Nancy U.
Publicado 2019